MDGL Q4 2021 Earnings — Madrigal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

MDGLMadrigal Pharmaceuticals, Inc.

$10B

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$65M

Net Income

-$65M

EPS (Diluted)

$-3.78

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$48M

Free Cash Flow

-$48M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$273M

Total Liabilities

$77M

Stockholders' Equity

$196M

Cash & Equivalents

$36M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$65M	-$60M	-8.5%
Net Income	-$65M	-$59M	-9.2%